The fibrosis-4 (FIB-4) index, a noninvasive tool for assessing liver fibrosis, has become a cornerstone in managing metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). Developed in 2006 by Dr. Richard K. Sterling and colleagues, FIB-4 was initially designed to predict advanced fibrosis (F3–F4) in patients with hepatitis C and HIV co-infection. This innovation aimed to reduce the reliance on liver biopsies, which were invasive and often disliked by patients.
Over the past two decades, its role has expanded significantly. The American Association for the Study of Liver Diseases (AASLD) now recommends FIB-4 as the initial risk stratification tool for identifying individuals at low, intermediate, and high risk for advanced fibrosis in MASLD and MASH, as well as for screening in other forms of liver disease like hepatitis C.
From Biopsies to Blood Tests: A Paradigm Shift
Before FIB-4, liver biopsy was the gold standard for assessing fibrosis, a procedure patients often found invasive and unpleasant. Dr. Sterling, motivated by the need for a less invasive alternative, developed FIB-4 using readily available data: age, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and platelet count. He noted that an AST/ALT ratio >1, in the absence of alcohol use, often indicated cirrhosis, and patients with cirrhosis typically had lower platelet counts due to portal hypertension and hypersplenism.
Strengths and Limitations: A Balancing Act
FIB-4’s strength lies in its high negative predictive value. A low FIB-4 score (less than 1.3) effectively rules out advanced fibrosis, particularly in suspected MASLD cases. However, its positive predictive value is less reliable. An raised FIB-4 score (greater than 1.3) suggests potential liver disease, but further confirmation through second-line tests like elastography or blood-based tests is often necessary. Scores above 2.7 or 3.25 may indicate advanced fibrosis, but this is not definitive, and these patients typically require additional testing.
FIB-4’s accuracy is influenced by factors like age, alcohol consumption, AST elevations, and abnormal platelet counts. It performs less well in younger patients (under 35) and older individuals, where age-adjusted thresholds (e.g., 2.0 for those over 65) may be more appropriate. Ongoing alcohol use can also skew results, as can conditions affecting AST levels or platelet counts, such as myositis, rhabdomyolysis, or immune thrombocytopenia.
While FIB-4 excels at initial screening, its utility in monitoring treatment progression is limited. Once treatment begins, liver enzymes may fluctuate, rendering FIB-4 less reliable for longitudinal assessment.
FIB-4’s Evolution and Future Prospects
The FIB-4 index has undergone significant evolution since its inception. Initially designed for hepatitis C and HIV co-infection, it has become a primary screening tool for MASLD and MASH. Dr. Sterling highlights its utility in ruling out advanced fibrosis, especially when repeated over time, but acknowledges its limitations in identifying moderate fibrosis stages. He notes that while FIB-4 is not ideal for detecting stage 2 or 3 fibrosis—the stages where intervention is most needed—it remains a valuable initial screening tool.
Addressing Unmet Needs in Liver Disease Assessment
Despite advancements, unmet needs persist in noninvasive liver disease assessment. Dr. Sterling stresses the importance of developing better markers for conditions like alcohol-related liver disease, where the AST/ALT ratio is less reliable. He also highlights ongoing efforts to create salivary tests, which could transform early detection by providing a cheap and accessible screening option. Furthermore, while modifications like FIB-5 and FIB-11 exist, they add complexity and cost without significant benefit, showing the need for targeted improvements.
Disclosures: Dr. Sterling reported advisory relationships with Calaris, Cima Sciences, and GSK. He has also received research funding from Madrigal, Atea, GSK, GigaGen, and Abbott and is chair of the AASLD Foundation Awards Committee. He is also part of the data and safety monitoring boards (DSMBs) for AskBio and Vertex.